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Use of Phage Display to Isolate Specific Human Monoclonal Antibody Fragments
Against a Potential Target for Multiple Myeloma
Pei Xiong Liew,1,2BSc (Hons), Feng Ge,1BSc, MSc, Charles Gullo,2BSc, PhD,
Gerrard KH Teoh,1,3MBBS, MMed (Int Med), FAMS, William YK Hwang,4,5MBBS, FRCP, FAMS

Abstract
Introduction: Multiple myeloma (MM), a malignancy of plasma cells, accounts for 10% of all
haematological malignancies and is currently incurable. Although it can be treated, the disease
tends to relapse after several years and becomes increasingly resistant to conventional therapy.
Investigations into using humoral therapy for MM are now underway with a view that novel
therapeutic agents may provide a more targeted therapy for MM. Materials and Methods:
Here, phage display, a faster and more efficient method compared to classical hybridoma fusion
technology, was used as a proof-of-concept to isolate several single-chain Fragment variables
(scFv) against Ku86. Results: Anti-Ku86 polyclonal scFvs biopanning was successful where
third round scFvs (A450~1.1) showed a 1/3 increase in binding as compared to the first round
scFvs (A450~0.4) with 100ug/mL of antigen (purified human Ku86). Subsequent selection and
verification of monoclonal antibodies using third round biopanning revealed 4 good affinity
binding clones ranging from A450~0.1 to A450~0.15 on 12.5ug/mL of antigen as compared to low
binders (A450~0.07) and these antibodies bind to Ku86 in a specific and dose-dependent manner.
Comparative studies were also performed with commercially available murine antibodies and
results suggest that 2 of the clones may bind close to the following epitopes aa506-541 and aa1374. Conclusions: These studies using phage display provide an alternative and viable method
to screen for antibodies quickly and results show that good affinity antibodies against Ku86
have been successfully isolated and they can be used for further studies on MM and form the
basis for further development as anti-cancer therapeutic agents.
Ann Acad Med Singapore 2009;38:621-9
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Introduction
Multiple myeloma (MM) is a malignant plasma-cell
neoplasm that is characterised by an excess of mature B-cells
in the bone marrow (plasmacytosis), in association with
secretion of monoclonal immunoglobulins (Ig) in serum and/
or urine, decreased normal Ig and lytic bone disease.1,2 MM
accounts for 10% to 20% of all malignant haematological
cancers and myeloma patients often have extensive
skeletal destruction, which are a main cause of morbidity
and mortality.2-4 Although MM can be treated, the disease
ultimately relapses in most cases and becomes increasingly
resistant to therapy until conventional options are exhausted,
prompting an urgent need for novel treatment.5 Major
1

advances have been made in the understanding of plasma
cell biology and the importance of the microenvironment
in MM development6-9 in the past decade, leading to the
development of newer agents such as thalidomide, its analog
lenalidomide10 and the proteasome inhibitor bortezomib.11
These agents have been used in combination with existing
agents against MM, but prospects of a cure of MM with
these agents is still uncertain and major limitations exist,
such as patient resistance and toxicities relating to the use
of these drugs.
Investigators are currently looking to immunotherapy
as a means of treatment for MM.12,13 Tumour-directed
monoclonal antibodies (mAb) or humoral therapy, have
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caused much excitement since the 1970s and with the
development of mAbs such as Rituximab (anti-CD20) and
Campath-1H (anti-CD52) for the treatment of lymphoma
and leukaemia.14 However, in the context of MM, the
major milestone to be crossed in this area is the selection
of a suitable surface antigen (Ag) to allow targeting by
antibodies against MM cells.
The Ku heterodimer is made up of 2 sub-units of
approximately 86 and 70kDa in higher eukaryotes which
binds to DNA. Identified in 1981 from Japanese patients
with scleroderma-polymyositis overlap syndrome, Ku
has now been found to play major roles in many cellular
processes.15 Foremost, Ku86 in association with Ku70 and
DNA protein kinase C plays a critical role in DNA repair
especially in non-homologous end joining (NHEJ) where
the lack of functional Ku proteins in the cell typically results
in genomic instability and hypersensitivity to DNA damage
as well as an increased likelihood of tumour development
and immunodeficiency.16-18 A comprehensive review of Ku
and its potential role in cancer, especially myeloma, has
been written by Gullo et al.19 Other cellular processes which
Ku has been found to partake in include antigen-receptorgene arrangements (Variable [Diversity] Joining {V(D)J}
recombination), gene transcription, apoptosis, telomere
maintenance, heat shock-induced responses and cell cycle
regulation20 which are important processes affecting tumour
metastasis. Therefore, it is clear that the Ku protein has an
integral and intrinsic role in cellular and organismal tumour
biology. Further, Ku86 has been discovered to translocate
to the cell surface of MM cells upon CD40L treatment21
and also mediate the binding of MM cells to fibronectin
and bone marrow stromal cells.22 Most importantly, the
mAb 5E2 directed against Ku86 were seen to induced
apoptosis of MM cells.22 Therefore, with Ku’s role in
tumour biology and its subsequent surface translocation,
surface bound Ku in MM provides an attractive target for
therapeutic antibodies.
In this present study, we have raised several monoclonal
single-chain Fragment variable (scFv) against Ku86.
Isolation of scFv was performed using phage display of a
human monoclonal antibody library instead of conventional
hybridoma technology, allowing us to bypass steps of
humanisation of the scFv to avoid issues of human antimouse antibody (HAMA) reactions commonly associated
with antibodies produced using hybridoma. Finally, the
isolated scFvs’ specificities and affinities were compared
to other known mAbs using competitive ELISAs.
Materials and Methods
Cell and Cell Culture
COS-7 cell line, a derivation of CV-1 which was estab-

lished from the kidney of an African green monkey, RPMI
8226 human MM (CCL-155) and CHO-K1 (CCL-61) was
purchased from American Type Culture Collection (ATCC,
Rockville, MD). EBV-negative SGH-MM5 human MM
cell line (CD10+, CD19-, CD20-, CD38+, CD40+, CD45+,
CD56+, CD138+) was developed previously in our laboratory23 from a patient with MM. COS-7 and CHO were
cultured in complete media consisting of 89% Dulbecco’s
modified Eagle medium (DMEM), 10% fetal bovine serum
(FBS) and 1% MEM non-essential amino acids while RPMI
8226 and SGH-MM5 were cultured in 90% RPMI 1640
with L-glutamine media, 10% FBS, 25IU/mL penicillin,
25ug/mL streptomycin and additional 5mM L-glutamine.
All cell lines were maintained at 37oC with 5% CO2 in a
humidified atmosphere.
Construction and Cloning of Ku86 gene into Mammalian
Expression Vector
Full-length 2.4kb Ku86 cDNA was obtained by RTPCR using QIAGEN RT-PCR kit (QIAGEN, Hilden,
Germany) according to manufacturers’ protocol. RT-PCR
was performed on total RNA extracted from SGH-MM5
and RPMI cell lines using QIAGEN RNAeasy (QIAGEN)
kit and the following oligonucleotides, Ku1 (forward:
5’-TGTATGGACGTGGGCTTTA CCAT-3’) and Ku2
(reverse: 5’-TCCACAGAGAATTAGATGATCCGCC-3’).
PCR products were then separated by 1.5% agarose
gel electrophoresis and cloned into Topo II TA vectors
(Invitrogen, Carlsbad, USA) for amplification in
Escherichia coli (E. coli) with 100ug/mL ampicillin
pressure and blue/white colony selection. Sequencing
was performed on the cloned Ku86 gene to ensure no
mutations. Next, 2 restriction enzyme sites, HindIII
at 5’ end and XbaI at 3’ end were engineered at the
ends of the cloned Ku86 using high fidelity PWO
SuperYield DNA polymerase (Roche Diagnostics,
Penzberg, Germany) with the following oligonucleotides
(forward: 5’-ATTAAAGCTTCCGGCAACATGG
TGCGGTCGGGGAATAAGGCAGCTGTTGTGC
T G T G TAT G G A C G T G G G C - 3 ’ ) a n d r e v e r s e :
5’-ATTATCTAGACTTATC ATGTCCAATAAATC-3’).
The engineered Ku86 gene was then sub-cloned into the
transient mammalian expression vector pcDNA3.1/mycHis B (Invitrogen) via digestion of the vector and cloned
gene at the 2 restriction sites with HindIII/XbaI before
ligating with DNA ligation kit (Stratagene, San Diego,
USA) at 4oC overnight. The resultant ligated product was
analysed with 1% agarose before transforming into E.coli
with 100ug/mL ampicillin selection for amplification.
Following overnight incubation, the recombinant plasmid
was extracted from transformed E.Coli via QIAprep Spin
Miniprep kit (QIAGEN) and sequenced.
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Expression and Purification of Ku86 Recombinant
Protein
The purified mammalian expression vector was
transfected into COS-7 cells for transient expression of
Ku86 recombinant protein. Transfection was performed by
incubating the plasmid and Lipofectamine2000 (Invitrogen)
with COS-7 cells grown to 90% confluence in 175cm2 large
flasks as per manufacturer’s protocol. CHO cell lines were
transfected similarly. After 24 hours, the cells were harvested
for assays and purification. For gene expression assays,
RNA of transfected COS-7/CHO cells were extracted using
QIAGEN RNAeasy (QIAGEN) as above and RT-PCR with
primers Ku1 and Ku2 was performed and analysed on 1%
agarose stained with ethidium bromide under UV light.
Transfected COS-7/CHO cell lysates, lysed with EBC1 lysis
buffer which contains 50mM tris pH 8.0, 150mM NaCl, 0.1%
NP-40, 0.5ug/mL phenylmethylsulfonyl fluoride (PMSF),
50mM NaF, 1mM NaVO4 and one Complete® protease
inhibitor tablet (Roche Diagnostics GmbH, Mannheim,
Germany) in every 50mL of lysis buffer, was used for
western immunoblotting as described. Untransfected COS-7
was used as negative control. Ku86 recombinant protein
was affinity purified using ProBond Nickel-Chelating Resin
column (Invitrogen) as per manufacturer’s protocol and
purified Ku86 was confirmed by western immunoblotting
as described. SYPRO Ruby Gel staining was performed
according to manufacturer’s protocol.
Western Immunoblotting
Proteins were quantified using Bradford’s method
(BioRad, Hercules, CA) and resolved (10ug/sample)
in a 12% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel. Subsequently, proteins
were transferred to a polyvinylidine difluoride (PVDF)
membrane (Schleicher & Schuell, Keene, NH) and blocked
for 2 hours with 5% skimmed milk in tris-buffered saline –
20mM tris pH 7.6, 150mM NaCl and 1% Tween-20 (SigmaAldirch, St Louis, MO) with an additional 0.2% Tween-20
(TBST). Membranes were probed using mouse monoclonal
antibody (mAb) S10B1 for primary hybridisation and goat
anti-mouse-HRP as secondary mAB 1:1000 dilution for 2
hours, then washed thrice with TBST before carrying out
chemiluminescene development with ChemiGlow reagents
and detection with filmless imaging on the FluoChem
Imager (both from Alpha Innotech, San Leandro, CA). For
re-probing of membranes, the experiments were repeated as
above but with the use of mouse anti-myc-HRP mAb.
Biopanning of Phage-scFvs against Ku86
The Tomlinson Library (MRC, Cambridge, UK)
was used for phage-scFv biopanning. Four hundred
micrograms of Ku86 in PBS was coated on Maxisorp
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immunotubes (Nalgene, Nunc, Roskilde, Denmark) for
4oC overnight and blocked with 2% skimmed milk in
PBS (MPBS) before addition of total 1012 phage/mL
phage-scFv library in 2% MPBS and hybridising for 2
hours at room temperature. Immunotubes were washed
with PBS before and after blocking. Immunotubes were
washed with PBS containing 0.1% Tween-20 ten times
(20 times for rounds 2 and 3) before eluting phage-scFv.
Panning was repeated twice with increased selection
stringency; for rounds 2 and 3, 40 micrograms of Ku86
in PBS was used for coating. Thereafter, phage-scFv was
eluted with either 0.1N glycine, 1% BSA, pH 2.2 (phages
rescued with M13K07 helper phage) or 1mg/mL trypsinPBS (phages rescued with KM13 helper phage) for latter
rounds and quantitated by colony forming units (CFU).
All eluted phage were amplified by TG1 cells with 100ug/
mL ampicillin and 50ug/mL kanamycin selection before
superinfection with either M13K07 or KM13 and purified
by Polyethylene glycol/NaCl precipitation. For polyclonal
phage ELISA, 1010 of amplified phage after panning were
added onto immunoplates as described. For monoclonal
phage ELISA, TG1 cells were infected with eluted phage
for 30 minutes at 37oC and spread onto TYE/amp plates.
After overnight incubation, TG1 colonies were randomly
selected and inoculated into 100uL of 2xTY containing
100ug/mL ampicillin overnight before individual clones
superinfection with M13K07 or KM13. Phage ELISA was
performed as described by using 100 microlitres of culture
supernatant containing phage particles. Monoclonal phage
verification was performed similarly by using the 7 best
binders and 7 randomly selected binders for ELISA.
Enzyme-Linked ImmunoSorbent Assay (ELISA) Analysis
To determine antigen-binding reactivity and sensitivity of
phage particles, serial dilutions (100ug/mL, 50ug/mL, 25ug/
mL, 12.5ug/mL and 6.25ug/mL) of purified Ku86 in PBS
were used to coat 96-well microtiter Maxisorp immunoplate
(Nunc) at 4oC overnight. For negative and positive controls,
100ug/mL of BSA for the former and 100ug/mL of anti-myc
antibody for the latter was used. For monoclonal screening,
12.5ug/mL of purified Ku86 was used. After blocking the
plate with 2% (w/v) MPBS, 1010 phage-scFv packaged
with either M13K07 or KM13 in 2% MPBS was applied to
each well for 1 hour at room temperature. After washing 3
times with PBS containing 0.1% Tween-20 (PBS-Tween)
and 3 times with PBS, the bound phage was detected with
anti-M13 antiserum conjugated with horseradish peroxidase
(Amersham Biosciences, GE Healthcare, Chalfont St. Giles,
UK). The signal was visualised with TMD substrate OptEIA
reagent (BD, San Diego, USA) and quantitated with ELISA
microplate reader (BioRad Model 3550, Hercules, CA) at
OD 450nm after stopping the reaction with 1M H2SO4.
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Monoclonal Phage-scFv characterisation Binding Assay
Characterisation of the binding epitopes of 2 of the best
binding scFv clones were performed by phage serial dilution
and competitive ELISA. Maxisorp Immunoplates were
coated with 50ug/mL of purified Ku86 in PBS overnight at
4oC and 100ug/mL of BSA was used for negative control.
For phage dilution, phage-scFv clones were serially
diluted 2 fold for ELISA. For competitive ELISA, 1 mL
of antibody mixture, which consisted of phage particles
and known murine monoclonal antibodies (either S10B1,
111, S5C11 or N9C1), in 2xTY was prepared while the
plate was blocked with 2% MPBS for 2 hours at room
temperature; murine monoclonal antibodies were added
in increasing amounts (2.0ug/mL, 4.0ug/mL, 8.0ug/mL,
16.0ug/mL) for each mixture. 100uL of the above antibody
mixtures was hybridised in each well for 2 hours at room
temperature before commencing washing and secondary
ELISA hybridisation which was performed as above.

Fig. 1a. Western blot result for the purification of Ku86 protein. The Ku86
recombinant proteins were purified using ProBond Nickel-Chelating Resin
column. ProBond Nickel-Chelating Resin exhibits high affinity and selectivity
for 6xHis-tagged recombinant fusion proteins of Ku86. (Lane 1: Whole
cell extract; Lane 2: Flow-through after binding; Lane 3: Flow-through
after washing; Lane 4: Concentrated pure Ku protein (Eluted with 250 mM
imidazole).

Results
Generation of Ku86 Antigen for Phage Display
In order to produce ScFv antibodies against the MM
surface antigen Ku86, the protein was cloned from MM
cell lines. Briefly, full length gene encoding Ku86 was
reverse engineered from MM cell lines and sub-cloned
into mammalian expression vector pcDNA3.1/myc-His
B. Restriction digest of the vector showed that the Ku86
gene was of the correct size (data not shown). In addition,
the cloned gene was fully sequenced to ensure that the
gene was in the correct orientation and contiguous reading
frame without any mutation. The purified pcDNA3.1 vector
was used to transfect COS-7 for expression of Ku86 and
Ku86 antigen from COS-7 cells was purified through a
Nickel-Chelating Resin column, which exhibits a high
affinity and selectivity for the six His-tagged recombinant
fusion protein of Ku86. Western immunoblotting was
performed after purification to confirm that recombinant
Ku86 was obtained (Fig. 1a). To examine and ascertain
whether transfected COS-7 cells expressed recombinant
Ku86 correctly, total protein from both transfected and
untransfected COS-7 were either stained with SYPRO
Ruby Protein Gel Stain or probed with anti-Ku86 antibodies
(S10B1) in Western immunoblotting (Fig. 1b). Purified
Ku86 was used as positive control, untransfected COS-7
was used as negative control and transfected/untransfected
CHO cells were used as a reference. The stains and probing
revealed that recombinant Ku86 was present in large
amounts in transfected COS-7 while untransfected COS7 cells do not express detectable levels of recombinant
Ku86. Transfected and untransfected CHO cell lines did
not express recombinant Ku86 at all.

Fig. 1b. SYPRO Ruby Gel Stain and Western blot result of Ku86 protein
expression. Total protein gel stain using SYPRO Ruby Stain (BioRad) and
Western immunoblotting using anti-Ku86 antibodies (S10B1) revealed that
Ku86 was present in large amounts in transfected Monkey cell line (COS-7)
but not the Chinese hamster ovary (CHO) cell line. Untransfected COS cells
do not express detectable levels of human Ku86. (Lane 1: Purified Ku protein;
Lane 2: Transfected CHO cell line; Lane 3: Untransfected CHO cell line; Lane
4: Transfected COS-7 cell line; Lane 5: Untransfected COS-7 cell line.

Biopanning and Screening for Polyclonal Antibodies against
Ku86 by Phage ELISA
Phage display biopanning allows for the simultaneous
screening and enrichment of the highest affinity binders.
The Tomlinson Library I was used to perform phage display
biopanning against the full length Ku86 protein to obtain
anti-Ku86 polyclonal antibodies. For the selection of good
affinity polyclonal antibodies, panning stringency was
increased from round 1 to 2 by decreasing the concentration
of antigen 10-fold and increasing the number of washes to
remove unspecific binders 2-fold. The phage library was
rescued either with trypsin-sensitive helper phage KM13
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Fig. 2a. ELISA readings for 3 rounds of polyclonal antibodies biopanning
rescued with M13K07 helper phage and eluted with non-specific acidic glycine
buffer. Biopanning results were indistinct at low concentrations of antigen
(6.25ug/mL). At antigen concentrations of 12.5ug/ml and above, Round 3,
the expansion and amplification round of biopanning shows more than 1/3
increase in ELISA absorbance and binding as compared to Round 1 ( ) and
2 ( ). BSA (100ug/mL) was used as negative control.

Fig. 2b. ELISA readings for 3 rounds of polyclonal antibodies biopanning
rescued with KM13 helper phage and eluted with specific trypsin treatment.
Biopanning results were inaccurate at low concentrations of antigen (6.25ug/
mL). At antigen concentrations of 12.5ug/ml and above, Round 3 ( ), the
expansion and amplification round of biopanning shows more than 1/3
increase in ELISA absorbance and binding as compared to Round 1 ( ) and
2 ( ). BSA (100ug/mL) was used as negative control.

(eluted with tryptic treatment) or commercially available
helper phage M13K07 (eluted with acidic glycine buffer).
As KM13 contains a modified gene 3 protein (pIII) which
is sensitive to tryptic digestion, rescued phages containing
only KM13 pIII and lacking wild-type pIII-scFv fusion
are rendered non-infective after tryptic treatment while
rescued phages with fusions are not cleaved and remain
infective for E.Coli amplification. In addition, to ensure that
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the ELISA signal reflects the phage-scFv binding activity
of each round accurately, different concentrations of the
antigen, Ku86, were used for ELISA plate coating. Figures
2a and 2b show the overall results of the biopanning and
screening via ELISA. In general, the affinity of phagescFv for Ku86 in both phage ELISAs were not substantial
for the first 2 rounds of panning as these initial rounds
of screening were used to weed out unspecific and low
affinity binders; the decrease in binding seen in round 2
was probably due to the increased panning stringency. As
initial rounds of biopanning are used to first select for strong
binders before amplifying them in the third round, phage
display biopanning was successful because polyclonal
scFvs demonstrated an exceptional level of binding with
more than one third increase in absorbance as compared
to rounds 1 and 2. Interestingly, phage particles eluted
non-specifically by acidic glycine buffer (Fig. 2a) showed
a better binding to Ku86 as compared to phage particles
eluted via trypsin treatment (Fig. 2b) by ~1.5 fold. It should
be noted that comparison of phage ELISA data are made
on a semi-quantitative basis.
Isolation of Individual Clones against Ku86 by Monoclonal
Phage ELISA
Based on these results, the third round of selection with
the library rescued with helper phage M13K07 was used
for isolation of monoclonal antibodies against Ku86.
The concentration of 12.5ug/mL of Ku86 was used as
this concentration provided a good representation of the
binding affinity of phage particles. To ensure that sufficient
clones were screened, phage particles were infected into
TG1, plated out such that individual colonies were well
separated before inoculating each colony into 96-well
plates (see methods). As each phage particle only encodes
for 1 antibody, picking individual bacterium allows us to
investigate the binding level of monoclonal antibodies
where ELISA absorbance readings are directly correlated
to strength and specificity of binding. Figure 3 illustrates
the binding affinities of 80 clones that were screened; all
clones bound to Ku86 in various degrees. The majority
of the clones had a rather low binding as judged by their
O.D. readings (0.03 to 0.06). There were approximately
13 modest affinity clones and 7 good binders (clones with
absorbance readings below 0.06 were classified as weak
binders, 0.06 to 0.08 as modest binders and readings above
0.08 as strong binders). As monoclonal phage particles
bind to specific epitopes, it is expected that the majority
of the clones do not bind well and that only a few clones
would have a high specificity and avidity for Ku86 which
was reflected in Figure 3. Furthermore, O.D. readings for
monoclonal strong binders are expected to be lower as
compared to polyclonal ELISA studies (O.D. ~ 0.22 at
12.5ug/mL) because the O.D. readings from polyclonal
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Fig. 3. ELISA readings for monoclonal antibody screening and selection.
ELISA plate wells were coated with 12.5ug/ml.The abscissa (A-J) denotes
the column which corresponds to the column of the 96-well plate and the
colored bars denotes the row of the 96-well plate. The ‘Strong binders’ (above
0.08absorbance) were A6, G6, G3, H6, H3, J8 and J2 and used for ELISA
phage verification

Fig. 4. ELISA results of monoclonal antibody phage verification. The ELISA
plate was coated with 12.5ug/ml of antigen. All stronger binders ( ) had a
better absorbance and affinity as compared to the random wells ( ) selected
for comparison. However, 3 of the strong binders ‘J2, J8 and H6’ had lower
than expected binding as compared to Figure 3. Wells H3, A6, G3 and G6
showed approximately 2-fold higher absorbance and increased binding
compared to the random wells.

screening measures the overall combinatorial binding
from all the monoclonal antibodies on different epitopes
which allows for increased antibody-antigen interactions
and higher readings.
Use of Phage ELISA to Verify Monoclonal Phage
Particles
To ensure that the monoclonal phage-scFvs that were
identified by ELISA screening were not false positives,
strong binders were further examined with randomly chosen
clones by phage ELISA at 12.5ug/mL Ku86 concentration.
As depicted in Figure 4, all strong binders had better
binding as compared to the 7 randomly selected binders in
general. Interestingly, 3 of the strong binders which were
chosen from monoclonal isolation (wells J2, J8 and H6)
had absorbance readings of OD650nm ~ 0.08-0.09 which were
approximately similar to the randomly selected binders and
were substantially lower as compared to previous findings.
Thus, for further confirmation, PCR was performed on the
7 strong binders and analysed on agarose gel. The PCR
analysis confirmed that wells H3, A6, G3 and G6 had fulllength variable heavy (VH) and variable light chain (VL)
while there were no bands seen for wells J2 and H6 and well
J8 had only half the required length. In addition, the strong
binders were sequenced and the Basic Local Alignment
Search Tool (BLAST) was performed, confirming the
above 4 wells had both VH and VL while the sequence of
J8 showed that no VH was present and wells J2 and H6
revealed sequences from the cloning vector only.

Fig. 5a. ELISA absorbance readings of phage ScFv-Ku86 dilution experiments.
Both ScFvs, A6 ( ) and G6 ( ) showed antigen-dependent binding.

Phage ELISA and Inhibition Experiments for Characterisation of Binding Epitopes
Anti-Ku86 monoclonal antibody candidates, clones
A6 and G6, which were identified by ELISA screenings,
were further examined to determine their binding sites on
Ku86 epitopes. They were thus tested as phage-scFvs in
conjunction with other known antibodies for their potential
to bind to Ku86 in competitive ELISAs. The first set of
experiments, illustrated in Figure 5a, shows that both
phage-scFv clones A6 and G6 bind to Ku86 in a specific
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decrease. G6/S5C11 and A6/N9C1 competitive experiments
did not reveal any significant change in binding levels (data
not shown). These results suggest that clone A6 and G6
may be binding near the aa506-541 epitope (S5C11) and
aa1-374 (N9C1) epitope, respectively.

Fig. 5b. Competitive ELISA assay for phage-ScFv A6 with S5C11 antibody.
Increasing amounts of S5C11 resulted in a 2/3 drop in absorbance reading
from ~0.2 to ~0.05 where further increases had no further effect.

Fig. 5c. Competitive ELISA assay for phage-ScFv G6 with N9C1 antibody.
Increasing amounts of N9C1 by half resulted in a ~1/5 drop in absorbance
readings at each dilution point.

and dose-dependent manner. Subsequently, to determine
the binding sites on Ku86, phage particles were incubated
in competitive ELISAs with several murine monoclonal
anti-Ku86 antibodies: S10B1, 111, S5C11 and N9C1, which
are specific for human and monkey Ku proteins. For S10B1
and 111 competitive ELISA assays, no significant change
in binding levels were seen with increasing amounts of
antibodies (data not shown), indicating that clones A6 and
G6 probably do not have recognition for epitopes targeted
by S10B1 (C-terminal) or 111 (N-terminal). Conversely,
competitive experiments of clone A6 with S5C11 revealed
dramatically decreased binding of A6 when S5C11
concentrations were increased (Fig. 5b) while competitive
experiments of clone G6 with N9C1 (Fig. 5c) showed a minor
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Discussion
The development of therapeutic antibodies has been
explored by many institutions and organisations because
of their potency in finding, and binding to, typically any
kind of molecule with high affinity and specificity.24
Examples of antibodies which have progressed from the
laboratory to the clinic include, but are not limited to, the
following: Rituximab and Zevalin (Anti-CD20) for NonHodgkin lymphoma, Alemtuzumab (Anti-CD52) for B-cell
lymphocytic leukemia and Mylotarg (Anti-CD33) for
acute myeloid leukaemia. As studies to isolate antibodies
against Ku using classical hybridoma technology were not
very successful in our laboratory (unpublished data) and
screening of recombinatorial phage display libraries for the
isolation prototype antibody against cancer have become
one of the main approach to therapeutic and diagnostic
drug discovery and validation, phage display technology
was used here to isolate several clones for further studies
on MM in the hope of developing the clones for therapeutic
use in the future. Antibody isolation was successful and
enhancement of mAbs can be subsequently performed via
molecular engineering or directed evolution if necessary.
Synthesising of whole and humanised anti-Ku86 antibodies
and subsequent scaling up antibody production in a GMP
facility as well as performing animal proof-of-concept
studies will be performed in future studies.
The Ku heterodimer plays a central role in several
nuclear processes ranging from DNA repair, telomere
maintenance to cell proliferation and apoptosis making it a
highly important regulatory protein.15,19,20,25 Indeed, recent
reports have implicated that the Ku protein (or its variant)
partakes in the development of several cancers, notably
MM.19 In MM, Ku has been shown to translocate to the
cell membrane upon CD40-activation and are involved
in homotypic and heterotypic cell-cell adhesion as well
as adhesion to fibronectin which protects the MM cell
from apoptosis triggered by irradiation or doxorubicin.21,22
Further, reports on Ku86 variant protein (Ku86v) expression
in MM have shown that increased expression of Ku86v is
correlated with an increased sensitivity to DNA damage.26
Finally, antibodies against surface Ku86 (5E2) were shown
to induce apoptosis in MM cells.22 Taken together, the
Ku protein could be an important candidate for anti-MM
drug development. Here, the generation of these human
scFv clones against Ku86 provides a potentially important
diagnostic tool, which can be used for further studies on
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the role of Ku, its variant and understanding their link to
the development of MM. Importantly, these clones form
the basis upon which an anti-MM therapeutic agent could
be engineered given that although there are several good
affinity antibodies directed against the Ku protein available
commercially at the moment, none of these are human in
origin or suitable for use as therapy.
The functional display of antibodies on phage particles
using large diverse combinatorial libraries opens
possibilities to select specific antibodies against proteins
or antigens of interest which subsequently allows for the
basis with which the antibody could be studied, improved
or altered.27 Screening of these libraries typically allows for
the selection of antibodies with high affinities, ranging from
micromolar to nanomolar affinity constants, depending on
the size and diversity of the library.28 Following screening
and binding selection, it is then possible to deduce the
primary structure of the binding site of the antibody by
sequencing the clone’s DNA due to the linking of phenotype
to the genotype encoding that molecule within the same
virion. Here, in this study, several scFv clones have been
isolated against the Ku86 protein using phage display as
a preliminary effort to target the effect of Ku86 in MM.
After selection, nucleotide sequence analysis have been
performed on the clones to confirm that selected clones
contained both human VH and VL sequences before
subjecting them to comparative studies with commercially
available Ku86 antibodies.
Since its advent approximately 30 years ago, the classical
hybridoma method is still being used to generate mAbs.29
Although this conventional technology has a successful
history, it has several intrinsic limitations: namely, its
relatively longer time span to isolate antigen-specific
antibodies (a time measured in months as compared to
weeks using phage display), its immunogeneticity where
murine antibodies may result in patients developing HAMA
reactions, presence of an affinity ceiling, the difficulty in
controlling in vivo selection conditions and the subsequent
antibody specificity and affinity. Antibody fragments or
single chain Fvs’, displayed on phage surfaces, bypass
these problems and allow for an in vitro optimisation
of antibodies against the specific antigen. Phage display
has proven to be a faster, more flexible and more reliable
alternative to generation and selection of antibodies.30
Carried out in the test tube, with human VH and VL chain
genes, the selection process is remarkably similar to the
natural affinity maturation process of affinity selection
and somatic hypermutation where it allows for tightly
controlled conditions, comparatively shorter time selection
without a need for superhumanising and isolation of human
antibodies with higher affinities that are not easily achieved
in hybridoma.

Despite the fact that phage display is relatively simple
to use and its phage particles are robust and stable, this
system has a few constraints such as library antibody
diversity limitation and erroneous amplification of a low
affinity clone30-33 and difficulties in the reproducibility of
the ELISA O.D. measurements. Antibody diversity and the
subsequent possibility of isolating high affinity antibodies
are directly linked to the size of the library. As the synthesis
and assembly of phage particles occurs in bacteria,
the DNA encoding the antibody needs to be imported
artificially. Thus, the recombinatorial library is limited
by bacterial transforming efficiency and this is presented
as a disadvantage where the largest reported libraries are
made of not more than 1x1010 to 1x1011 members currently.
Amplification of antibodies during screening is directly
linked to the phage with the highest growth advantage
(with or without antibody fusion) and combined with the
‘sticky’ properties of phages, therein lies the possibility
that only low affinity clones dominate a population after
screening (erroneous amplification). A low affinity clone
may arise due to several factors such as the failure of the
antibody fragment to be expressed or folded properly, the
susceptibility of the clone to proteolysis or the fact that the
fragment is toxic to the host and forming aggregates which
slows down or stops bacterial growth.30
In summary, the experiments described here have isolated
good affinity scFvs against Ku86. These clones form the
basis upon which further experiments can be performed to
develop the antibodies into therapeutic anti-cancer agents.
Further, here we show that an established method (phage
display) other than the classical hybridoma technology
could be used for antibody selection as a proof of principle
that mAbs may be generated in a shorter period of time
and, because a recombinatorial human antibody library
was used, could offer a significant clinical advantage over
murine antibodies by avoiding HAMA reactions.
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